No, Neuralink is not publicly traded. Retail investors mostly have to wait for an IPO, look at public peers like Medtronic and Boston Scientific, or — if accredited — explore private secondary markets.
No, Neuralink is not publicly traded. Retail investors mostly have to wait for an IPO, look at public peers like Medtronic and Boston Scientific, or — if accredited — explore private secondary markets.
Neuralink is one of the most closely watched private companies in the market right now because it sits at the intersection of Elon Musk, brain-computer interfaces, and real clinical progress. The company has kept expanding its patient program through 2024 and 2025, and its latest reported fundraising put a fresh spotlight on just how valuable private investors think it could become.
That combination naturally sends retail investors searching for a way in. The problem is that Neuralink is still private, so the path to ownership is very limited. Here’s what Neuralink does, whether it trades publicly, what an IPO would require, and the realistic ways investors can get exposure today.
What is Neuralink?
Neuralink develops brain-computer interface systems designed to let people control computers using neural signals. Its current work centers on the N1 Implant, the R1 Robot, and the N1 User App, which it is testing in the PRIME Study for people with paralysis. The company says the implant records neural activity through 1,024 electrodes across 64 threads.
Neuralink was founded in 2016 and is headquartered in Fremont, California. It is still in a clinical-stage, pre-revenue phase, and the company has not publicly disclosed revenue or an official employee count on its site. Its stated mission is to restore autonomy for people with unmet medical needs, which is why it has drawn so much attention from both biotech and tech investors.
Is Neuralink publicly traded?
No, Neuralink is currently a privately held company, so there is no Neuralink stock ticker for retail investors to buy on a public exchange. SEC records show Neuralink Corp. filing Form D exempt offerings, not a public registration statement, and there is no public parent company behind it.
That means ownership is still concentrated in private hands, with reporting indicating the company remains founder-controlled and Musk-controlled rather than publicly owned. If you want shares, you are not buying them through a normal brokerage account today.
When will Neuralink go public?
There is no filed S-1 and no publicly announced IPO timetable. The clearest public signal in the record is fundraising, not a listing process: Neuralink’s most recent reported round was a June 2025 Series E at a $9 billion pre-money valuation, after earlier reporting in 2025 pointed to a raise around an $8.5 billion pre-money valuation.
For would-be investors, the key things to watch are a real SEC registration filing, formal IPO commentary from the company, and any shift from clinical expansion toward a public-market process. Until that happens, any IPO talk is just speculation.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
For most retail investors, the realistic options are limited. First, you can wait for an IPO if Neuralink ever decides to go public. If that happens, you would typically be able to buy shares through a brokerage account once trading begins, though getting an allocation at the offering price is usually harder than just buying in the open market.
Second, there is no public parent stock to buy, because Neuralink is not a subsidiary of a listed company. Third, most retail investors who want exposure end up looking at public comparables instead — companies with implantable-device, neuromodulation, or medical-device expertise. Fourth, accredited investors may sometimes find Neuralink shares on private secondary markets, but that route is restricted, illiquid, and not available to most people.
The honest answer is that there is no easy retail backdoor to Neuralink ownership. If you are not accredited and the company stays private, the closest practical path is to own public companies that operate in adjacent medical-device markets.
Closest publicly-traded alternatives
The closest public alternatives shareholders look at are Medtronic (MDT), Boston Scientific (BSX), and Abbott (ABT). Medtronic is a broad medical-device leader with neuromodulation exposure and deep clinical/regulatory experience. Boston Scientific is another major implantable-device company with neuromodulation and electrophysiology exposure. Abbott is a useful proxy because it competes in implantable medical-device infrastructure and adjacent neuromodulation markets.
These are not Neuralink clones — Neuralink is still a pre-commercial brain-computer interface company — but they are the most liquid public names investors use when they want exposure to the broader device and neuromodulation theme. If you want a more specialized pure-play proxy, LivaNova (LIVN) is also relevant, but the three above are the most mainstream comparables.
Recent news
The biggest recent development was Neuralink’s reported June 2025 Series E fundraise at a $9 billion pre-money valuation. Earlier 2025 reporting also pointed to a raise around an $8.5 billion pre-money valuation, which shows how much private-market interest remains in the company.
On the operating side, Neuralink’s site shows implanted patients in Jan. 2024, Jul. 2024, Nov. 2024, Feb. 2025, and Apr. 2025, signaling continued clinical expansion. The company also maintained active patient-registry materials in the U.S., U.K., and Canada during 2024–2025.
Verdict
If you want Neuralink specifically, the blunt answer is that you cannot buy it like a normal public stock today. The company is private, there is no IPO filing, and the only direct access path mentioned in the market is private secondary trading for accredited investors.
For everyone else, the actionable route is to watch for an eventual IPO and, in the meantime, use public peers like MDT, BSX, and ABT as the closest listed exposure to the broader implantable-device and neuromodulation space. That is the realistic way most retail investors can participate in the theme.
▌Common Questions
Frequently asked questions
+Is Neuralink publicly traded?
No, Neuralink is currently a privately held company, so there is no Neuralink stock ticker for retail investors to buy on a public exchange. SEC records show Neuralink Corp. filing Form D exempt offerings, not a public registration statement, and there is no public parent company behind it.
+When will Neuralink go public?
There is no filed S-1 and no publicly announced IPO timetable. The clearest public signal in the record is fundraising, not a listing process: Neuralink’s most recent reported round was a June 2025 Series E at a $9 billion pre-money valuation, after earlier reporting in 2025 pointed to a raise around an $8.5 billion pre-money valuation.
+How can you invest in Neuralink?
For most retail investors, the realistic options are limited. First, you can wait for an IPO if Neuralink ever decides to go public. If that happens, you would typically be able to buy shares through a brokerage account once trading begins, though getting an allocation at the offering price is usually harder than just buying in the open market.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
